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Abstract
Background: In experimental conditions alveolar fluid clearance is controlled by alveolar b2-adrenergic receptors. We
hypothesized that if this occurs in humans, then non-selective b-blockers should reduce the membrane diffusing capacity
(DM), an index of lung interstitial fluid homeostasis. Moreover, we wondered whether this effect is potentiated by saline
solution infusion, an intervention expected to cause interstitial lung edema. Since fluid retention within the lungs might
trigger excessive ventilation during exercise, we also hypothesized that after the b2-blockade ventilation increased in excess
to CO2 output and this was further enhanced by interstitial edema.
Methods and Results: 22 healthy males took part in the study. On day 1, spirometry, lung diffusion for carbon monoxide
(DLCO) including its subcomponents DM and capillary volume (VCap), and cardiopulmonary exercise test were performed. On
day 2, these tests were repeated after rapid 25 ml/kg saline infusion. Then, in random order 11 subjects were assigned to
oral treatment with Carvedilol (CARV) and 11 to Bisoprolol (BISOPR). When heart rate fell at least by 10 beats?min21, the
tests were repeated before (day 3) and after saline infusion (day 4). CARV but not BISOPR, decreased DM (21367%,
p = 0.001) and increased VCap (+20622%, p = 0.016) and VE/VCO2 slope (+1268%, p,0.01). These changes further increased
after saline: 218613% for DM (p,0.01), +44628% for VCap (p,0.001), and +20610% for VE/VCO2 slope (p,0.001).
Conclusions: These findings support the hypothesis that in humans in vivo the b2-alveolar receptors contribute to control
alveolar fluid clearance and that interstitial lung fluid may trigger exercise hyperventilation.
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Introduction
During acute fluid overload, gas exchange in the lungs is
preserved as a result of at least two major mechanisms. First, part
of the fluid is accumulated within the interstitial space and around
the small airways, thus retarding the formation of alveolar edema
[1,2]. Second, fluid permeating the alveolar-capillary membrane is
reabsorbed as a result of Na+ transport systems located on the
alveolar surface [3,4] and controlled by the b2 adrenoreceptor
system [5,6]. The involvement of these receptors has been
reported in several animal and ex-vivo human lungs studies
documenting an increase in alveolar fluid reabsorption upon
stimulation of the b2-alveolar receptors by endogenous and
exogenous catecholamine [4,7,8]. Fluid reabsorption from the
alveolar and interstitial compartments to the vascular bed has also
been invoked to explain the gradual recovery of gas exchange over
time at high altitude [9,10].
In vivo in humans fluid accumulation within the interstitial lung
compartment can be estimated from the changes of lung diffusion
capacity for carbon monoxide (DLCO) [11]. The test is the result
of two in series resistive components with the first describing the
passage of carbon monoxide (CO) through the alveolar-capillary
membrane (membrane diffusion, DM), and the latter the
combination of the gas with hemoglobin, from which the capillary
volume (VCap) can be computed [12]. In heart failure (HF),
gradual accumulation of fluid across the lungs leads to a decrease
of gas exchange capacity [13] presumably when fluid accumula-
tion in the interstitial space and reabsorption by alveolar Na+
transport systems are fully exploited. Under these conditions,
reduced DLCO and/or DM have been consistently reported to be
associated to a reduced exercise capacity [13,14], reduced
ventilatory efficiency [15] and poor prognosis [16]. b-blockers
are among the cornerstone tools for HF treatment [17,18] but
substantial functional differences have been documented within
this class of medications. For instance, in contrast to Bisoprolol
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(BISOPR), Carvedilol (CARV) has been shown to reduce DLCO
in HF patients [19,20]. This has been interpreted as a result of
different mechanisms of these b-blockers on the alveolar b2-
receptors and therefore on fluid flux across the lung, though this
hypothesis has never been proved [21].
This study was conceived to clarify the role of the alveolar b2-
receptors on reabsorption of lung fluid in humans in vivo and see
whether interstitial lung edema affects the ventilatory efficiency
during exercise. Our first postulate was that by blocking the b2-
adrenoreceptors with CARV, a non-selective b1-b2blocker, DM
decreased as a result of the reduced lung fluid reabsorption. This
hypothesis was tested in 11 healthy subjects by measuring the DM
changes after a short course of oral CARV. Eleven healthy
subjects treated with BISOPR, a selective b1-blocker, represented
the control group. To further explore the role of the alveolar b2-
receptors in regulating fluid kinetics across the lung interstitium,
the experiment was repeated after infusing saline solution, an
intervention expected to increase lung fluid within the interstitial
lung compartment [22]. Under these conditions we predicted that
CARV would be associated with a further decrease in DM as a
result of the inability of the inactivated b2-receptors to clear the
fluid out of the alveolar compartment. The second hypothesis that
interstitial lung edema contributes to drive minute ventilation (VE)
during exercise was tested in the same groups of subjects by
examining the changes of the slope of the regression analysis
between VE and carbon dioxide production (VCO2) as a function
of DM before and after CARV, BISOPR and saline solution
infusion. The prediction was that if interstitial lung edema is a
determinant of exercise hyperventilation, then the slope of VE vs.
VCO2 should increase with the decrease in DM.
Methods
Patient population and study protocol
Twenty-two healthy volunteers selected from the medical staff
participated in the study. Inclusion criteria were age between 20–
60 years, male sex, no smoking history, absence of contraindica-
tions to b-blocker therapy, systolic blood pressure at rest ranging
from 120 to 140 mmHg, diastolic blood pressure 70–80 mmHg,
heart rate (HR) at rest .60 bpm, normal clinical evaluation,
history, standard spirometry, echocardiogram and cardiopulmo-
nary exercise test. Among the exclusion criteria were history and/
or clinical evidence of any cardiovascular or pulmonary or
systemic disorders contraindicating the test or affecting the
functional response to exercise, any conditions requiring daily
medications, and inability to adequately perform the required
maneuvers for pulmonary function tests. The protocol was
approved by the local Ethics Committee (Institutional Review
Board no. S154/319, date13/04/2011), and written informed
consent was signed prior to the study. The study was registered as
EudraCT 2010-020357-14.
Study protocol
Pre-study day. The subjects underwent clinical examination,
including blood pressure, HR, and cardio-pulmonary exercise test
(CPET) on a cyclo-ergometer for familiarization purposes. If the
inclusion/exclusion criteria were met, the subjects were informed
of the aim and protocol of the study and requested to sign the
consent.
Study days. The subjects attended the laboratory on four
different occasions whose sequence is shown in Figure 1. On day 1,
standard pulmonary function tests, DLCO measurement including
its subcomponents DM and VCap, and CPET were performed. On
day 2, the same tests were repeated after infusion of saline solution
at the dose of 25 ml/Kg in less than 30 min. Then, the subjects
were randomized to receive either oral CARV (11 subjects) or
BISOPR (11 subjects), respectively. In the following days the dose
of b-blocker was up-titrated until HR decreased by at least 10
beats?min21. Thereafter, lung function tests, DLCO, DM, VCap
and CPET were retested before (day 3) and after saline solution
infusion (day 4). b-blocker treatment was conducted for at least 5
days to achieve the desired decrease in HR. Study days 1 and 2
and study days 3 and 4 were separated by no more than 48 hours
from each other.
Spirometry and DLCO measurements
Spirometry was performed according to current guidelines with
a mass flow-meter (SensorMedics, Yorba Linda, CA) [23].
Predicted values are from Quanjer et al. [24].
DLCO and its subcomponents DM and VCap were measured
with the single-breath method by breathing gas mixtures
containing three different O2 concentrations (21%, 40% and
60%) and 0.3% CO and 0.3% methane (CH4) according to
Roughton and Forster [12]. DLCO after saline infusion was
corrected for a difference of Hb of 0.57 g/dL vs. control
conditions, a value derived from a previous study conducted with
the same amount of saline/Kg [25]. Alveolar volume was
estimated from the CH4 decay slope during constant expiratory
flow measurement [26]. Measurements at each mixture were
performed at least in duplicate and according to the standard
requirements and acceptability criteria of current guidelines [11].
The gas exchange measurements were performed with a V-max
2900 metabolic cart (Sensor Medics, Yorba Linda, CA).
Cardiopulmonary exercise test
A symptom-limited incremental exercise test was performed on
an electronically braked cycle ergometer (Erg 800S, SensorMedics,
Yorba Linda, CA). A personalized ramp protocol was designed to
achieve maximum load in 1062 minutes in each subject [27]. The
volunteers wore a nose clip and breathed through a mass flow
sensor connected to a saliva trap. Ventilation and respiratory gases
were measured breath by breath (V-max 2900 metabolic cart,
Sensor Medics, Yorba Linda, CA) and then averaged every 20 s
for analysis. HR and 12-lead ECG were monitored continuously,
hemoglobin saturation was recorded by an ear oxymeter, and
blood pressure was monitored with a cuff sphygmomanometer at
rest and at peak exercise. Anaerobic threshold (AT) was measured
according to standard technique [28]. VE/VCO2 slope was
measured from the beginning of loaded pedaling to the end of the
isocapnic buffering period [29].
Statistical analysis
Data are reported as mean 6 SD. Differences between study
days or treatment groups were analyzed as percent changes of day
1. The effects of saline infusion were examined by paired Student’s
t-test, whereas the effects of medications with and without saline
infusion by unpaired Student’s t-test. Statistical significance was
accepted at p,0.05 to reject the null hypothesis. Correlation
between variables was assessed by linear regression analysis. The
sample size of 11 subjects per group provided a 90% power to
detect changes in DM by 10 mL?mmHg
21?min21 and VE/VCO2
slope by 5 L?min21 after CARV and saline infusion with an
alpha= 0.05.
Data were stored in an Excel database and then analyzed by
SPSS 17.0 (SPSS Inc., Chicago, IL).
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Results
The main anthropometric and functional data at rest and peak
exercise of day 1 are reported in Table 1.
Effects of saline infusion (day 2)
Saline solution infusion was associated with a slight but
significant decrease in FVC, FEV1 and alveolar volume. DM
and DLCO remained unchanged whereas VCap increased
(p = 0.006). Exercise capacity was not significantly modified by
the intervention. Ventilation efficiency was significantly reduced
after saline infusion as documented by the 1069% increase of the
VE/VCO2 slope (p,0.001). No correlations were found between
the changes in VE/VCO2 and any of the DLCO parameters after
saline infusion. The main results are shown in figures 2A and B.
Effects of b-blockade (day 3)
Average daily doses of CARV and BISOPR were 2560 mg and
6.662.8 mg, respectively. Both treatments led to similar decre-
ments in resting HR (1767 and 1567 beats?min21 for CARV and
BISOPR, respectively). FEV1 and FVC slightly but significantly
decreased with CARV (p,0.05 and p,0.01, respectively) but not
with BISOPR. In contrast, DM and VCap exhibited significantly
larger changes with CARV (p,0.01 and p,0.05, respectively)
than BISOPR. Again, DLCO remained unmodified by any
treatments. At peak exercise HR was lower than at day 1 in both
groups (p,0.001 for both). The VE/VCO2 slope significantly
increased with CARV compared to BISOPR (p,0.001). None of
the other parameters were significantly modified by the b-
Figure 1. Design of the study. Legend: DLCO= Lung diffusion for carbon monoxide; CPET=Cardiopulmonary exercise test; HR=Heart rate.
doi:10.1371/journal.pone.0061877.g001
Table 1. Main anthropometric and functional parameters at
rest and peak exercise.
Number of subjects 22
Age, years 40612
Height, cm 180610
BMI, kg?m22 25.363.6
FEV1, L (% pred) 4.2060.60 (107611)
FVC, L (% pred) 5.1060.60 (105611)
DLCO, mL?mmHg21?min21 (% pred) 31.864.7 (97612)
DM, mL?mmHg
21?min21 57.2612.3
VCap, mL 94.4625.5
VA, L 6.460.7
Load, watt (% pred) 206635 (95618)
HR max, min21 (% pred) 167613 (9665)
VO2 peak, ml?min
21 (%) 33.566.4 (90617)
VE/VCO2 slope 23.163.1
Legend: BMI = Body mass index; FEV1 = Forced expiratory volume in 1 second;
FVC = Forced vital capacity; DLCO=Diffusing lung capacity for carbon
monoxide; DM=Membrane diffusion; VCap =Capillary volume; VA =Alveolar
volume; HR=Heart rate; VO2peak =Oxygen uptake at peak exercise; VE/VCO2
slope = slope of the linear regression analysis of VE plotted vs. VCO2.
doi:10.1371/journal.pone.0061877.t001
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blockade. No correlations were observed between the changes in
VE/VCO2 and in DLCO or any of its subcomponents after either
b-blocker treatments. The main results are shown in figures 3A
and 3B.
Effects of saline solution infusion under CARV and
BISOPR conditions (day 4)
After either b-blockers, saline infusion caused mild reductions in
FEV1 and FVC. With CARV DM and VCap were significantly
reduced and increased, respectively. Their changes were larger
than at day 3 (p,0.02 for both). With CARV the increase in VCap
was larger than with BISOPR (p,0.02) (figure 4A). Exercise
capacity was preserved with either treatments. However, the VE/
VCO2 slope significantly increased more with CARV than
BISOPR (figure 4B) (p = 0.02). No significant correlations were
found between the changes in VE/VCO2 and in any lung
diffusion parameters with CARV.
Discussion
The main results of this study are that, compared with BISOPR,
CARV was associated with a significant reduction in DM and
increment in VCap, that were larger when the test was preceded by
saline infusion. As CARV is a non-selective b-blocker, these
findings support the hypothesis that alveolar b2-adrenergic
receptors play a significant role in controlling alveolar fluids
reabsorption in vivo in humans. In addition, the significant
increment in VE/VCO2 observed with CARV but not with
BISOPR either before or after saline solution infusion suggests that
interstitial lung edema may contribute to exaggerate the ventila-
tory response to exercise in humans.
Interpretation of results and limits of the study
b2-adrenergic receptors are expressed all throughout the lung
including the alveolar space where they regulate several key
proteins needed for ion and fluid transport. This has been
documented in rat and sheep alveolar epithelial cells as well as in
human lung cells [30]. Even though also the alveolar b1-
adrenergic receptors can accelerate alveolar active sodium
transport [31], data on alveolar b2-adrenergic receptors knockout
mice suggest that it is the b2 receptors that are responsible for the
most of the b-receptor mediated fluid reabsorption [32]. No data
are available in vivo in humans.
To test the hypothesis that alveolar b2-adrenergic receptors
contribute to regulate fluid homeostasis within the alveolar
compartment in humans in vivo we examined the changes in
DM, a very sensitive marker of fluid accumulation within the
interstitial lung compartment, after blocking the alveolar adren-
ergic receptors and over-hydrating the lung. With the latter
intervention, VCap increased presumably as a result of the
recruitment or over-distension of the pulmonary capillaries. This
Figure 2. Changes of the main functional parameters at rest
(panel A) and with exercise (panel B) after saline infusion with
respect to baseline conditions. Legend: FVC= Forced vital capacity;
FEV1 = Forced expiratory volume in 1 second; DLCO= Lung diffusion for
carbon monoxide; DM=Membrane diffusion; VCap = Capillary volume;
VA=Alveolar volume; HR=Heart rate; VO2peak =Oxygen uptake at
peak exercise; VE/VCO2slope= slope of the linear regression analysis of
VE plotted vs. VCO2 from the beginning of loaded pedaling to the end
of the isocapnic buffering period. Statistical differences were examined
by paired Student’s t-test. Symbols denote statistical significance
(** = p,0.01; *** = p,0.001).
doi:10.1371/journal.pone.0061877.g002
Figure 3. Changes in the main functional parameters at rest
(panel A) and with exercise (panel B) after Carvedilol (empty
figures) and Bisoprolol (full figures) with respect to baseline
conditions. Statistical differences were examined by unpaired
Student’s t-test. Legend as in figure 2. Symbols denote statistical
significance (* = p,0.05; ** = p,0.01; *** = p,0.001).
doi:10.1371/journal.pone.0061877.g003
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was associated with a decrease in DM consistent with fluid
accumulating also along the alveolar capillary membrane and
presumably within the space around the small airways. DLCO did
not change as a result of the opposite changes in DM and VCap that
compensated each other. A very mild restrictive pattern also
occurred, as suggested by the decrease in FEV1 and FVC. These
data are in line with previous reports, where infusion of a similar
amount of saline had similar effects in lung function [33,34,35,36]
and DLCO [6,25,37].
With CARV, DM significantly decreased, presumably because
the b2-blockade was such that the active pumps located on the
alveolar surface and necessary to pump fluid out of the alveolar
compartment were down-regulated. However, the increase in
VCap was quite a surprising finding and difficult to explain.
Because b-blockers are not known to increase cardiac output in
healthy subjects, we postulate that the increase in VCap could have
been the result of some local feed-back control to maintain
constant gas exchange counterbalancing DM reduction [13]. Can
these data support the hypothesis that the alveolar b2-receptors in
vivo in humans contribute to keep fluid homeostasis across the
alveolar-interstitial membrane? We believe this is the case for the
following reasons. First, DM is a very sensitive functional index of
the alveolar-capillary membrane as it estimates the CO gradient
between the two compartments [12], and as such, is a reflection of
the interstitium morphology [13]. As there were no other reasons
for DM to decrease in our study, these findings strongly suggest
that blocking the alveolar b2-adrenergic receptors with CARV
allowed some fluid to be accumulated within the lung interstitium.
Second, in animals models, infusion of saline solution was
associated with interstitial and airway wall edema [1], and in
HF infusion of even small amount of saline was associated with gas
exchange worsening [37,38]. What our study documents is that
pharmacological inhibition of the b2-receptors led to functional
findings very similar to saline infusion at the level of the alveolar-
capillary membrane. Given the bulk of evidence that alveolar b2-
receptors regulate fluid clearance through the active Na+ channels
at least in vitro [3,5], the decrease in DM after CARV lends
support for the first time to the hypothesis that the alveolar b2-
receptors control the fluid homeostasis in vivo in humans across the
alveolar-capillary membrane.
In animals, induced pulmonary vascular congestion stimulates
the pulmonary C-fibers [39,40] that in turn trigger rapid shallow
breathing [41]. Studies in HF patients [15] and in healthy subjects
before and after saline infusion documented an excess of
ventilation with respect to the CO2 produced during exercise
[25], suggesting that interstitial lung edema could contribute to
cause hyperventilation during exercise. At a first glance, our
findings appear to negate this hypothesis as no correlations were
observed between the increase in VE/VCO2 slope and decrease in
DM. Yet despite the lack of this kind of evidence we believe that
the idea that interstitial lung edema can trigger exercise
hyperventilation is still true for a series of reasons. First, the
increase of the VE/VCO2 slope was always coincident with the
decrease of DM no matter how the latter was achieved with saline
solution infusion, CARV, or both. When BISOPR was given
instead of CARV, DM remained unmodified by treatment, and so
did the VE/VCO2 slope. Second, when the changes in VE/VCO2
were plotted against the changes in DM on all study days, a clear
relationship became apparent (figure 5), suggesting that VE
increased in excess to the VCO2 when DM was reduced. If this
reinforces our original hypothesis that interstitial lung edema
significantly contributes to reduce the ventilator efficiency during
physical exercise, this does not deny that other mechanisms
regulate ventilation during exercise especially in disease. For
instance, in chronic HF, CARV, as opposed to BISOPR and the
present findings in healthy humans, has been shown to reduce the
VE/VCO2 slope [39] presumably because of its effects on the
overactivated chemoreflex. Therefore, we acknowledge the overly
simplicity of our model with respect to HF, a disorder where much
of exercise hyperventilation is sustained not only by interstitial lung
edema but also altered autonomic reflex control, lung vascular
pathology and functional dysfunction, physical deconditioning,
early occurrence of metabolic acidosis with exercise, and neural
afferent signals from exercising muscles and systemic circulation
[42,43,44]. As a second limit of the study, we also concede that a
random cross-over design of the study could have provided more
solid evidence about the effects of CARV on the alveolar b2-
receptors blockade with respect to BISOPR. Yet, in designing the
trial we considered this at a higher risk of drop-out than the
double-blind random design because of the excessive burden of
invasive tests and treatment for the participants.
Clinical implications
HF is a complex disease where fluid accumulation within the
interstitial space and exercise hyperventilation are the only two
features reproduced in our model. Yet, our findings may offer
important considerations for the clinical approach to the disease.
If interstitial lung edema is a key issue of the disease and
presumably plays a substantial role to reduce the ventilatory
efficiency during exercise, then it is wondered what is the best
functional index for clinical follow-up. The decrease of FEV1 and
Figure 4. Changes in the main functional parameters at rest
(panel A) and with exercise (panel B) after saline infusion
under Carvedilol (empty figures) and Bisoprolol (full figures)
conditions with respect to baseline conditions. Statistical
differences were examined by unpaired Student’s t-test. Legend as in
figure 2. Symbols denote statistical significance (* = p,0.05;
** =,0.01;*** = p,0.001).
doi:10.1371/journal.pone.0061877.g004
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FVC with CARV was significant from a statistical point of view
but quite small and on average well within the limits of natural
variability of the measurements over time [23], thus limiting their
use in routine practice. DLCO appears to be a quite insensitive
parameter to examine the perturbations of gas exchange with b-
blockers and fluid accumulation within the lung interstitium. This
is because the changes in its subcomponents tend to compensate
each other, thus leaving DLCO unchanged. Measuring DM
appears to be a realistic alternative as it directly estimates the
morphological changes at the alveolar-capillary membrane level. It
remains to demonstrate the impact of such a functional test in
clinical practice.
As a corollary, our data also suggest that non-selective b-
blockers are not indicated in the presence of clinical and/or
radiological signs of fluid accumulation within the lung.
Conclusions
The present study shows that in healthy subjects CARV, a non-
selective b1 and b2 blocker, was significantly associated with a
decrease in DM, especially after saline infusion. As this finding was
not replicated with BISOPR, a selective b1 blocker, we speculate
that the decrease in DM was the result of a blockade of the alveolar
b2-adrenergic receptors known to control the active Na
+ transport
of fluid out the alveolar and interstitial lung compartments. The
decrease in DM was associated with an increase in the VE vs.
VCO2 slope during exercise, thus suggesting that fluid accumu-
lation within the interstitial lung compartment may contribute to
trigger hyperventilation during exercise, thus reducing the
ventilator efficiency. These findings may represent the basis for a
more physiologically oriented b-blocker use in HF.
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